Competition and price among brand-name drugs in the same class: A systematic review of the evidence.

ABSTRACT:

Background

Some experts have proposed combating rising drug prices by promoting brand-brand competition, a situation that is supposed to arise when multiple US Food and Drug Administration (FDA)-approved brand-name products in the same class are indicated for the same condition. However, numerous reports exist of price increases following the introduction of brand-name competition, suggesting that it may not be effective. We performed a systematic literature review of the peer-reviewed health policy and economics literature to better understand the interplay between new drug entry and intraclass drug prices.

Methods and findings

We searched PubMed and EconLit for original studies on brand-brand competition in the US market published in English between January 1990 and April

SUBMITTER: Sarpatwari A 

PROVIDER: S-EPMC6667132 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature